Bayer (BYR.L,BAYRY.PK,BAYZF.PK) said its cooperation partner, Janssen Research & Development, LLC has submitted supplemental New Drug Applications to the U.S. Food and Drug Administration, or FDA, seeking approval for the use of the oral anticoagulant Xarelto (rivaroxaban) to treat patients with deep vein thrombosis, or DVT, or pulmonary embolism, or PE, and to prevent recurrent venous thromboembolism, or VTE.
The submissions are supported by data from the global EINSTEIN program, which included almost 10,000 patients. The three Phase III studies evaluated the safety and efficacy of rivaroxaban in the treatment of DVT and PE and the prevention of recurrent VTE.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.